Hepalink gains rights to Resverlogix's RVX-208 in China

Shenzhen Hepalink Pharmaceutical Co. Ltd. (Shenzhen, China) gained exclusive development and commercialization rights to RVX-208 from Resverlogix Corp. (TSX:RVX) in greater China.

Resverlogix President and CEO Donald McCaffrey told BioCentury the deal offers an opportunity to enter the China market with a global partner and enough capital to pursue several new indications for RVX-208. Shenzhen Hepalink will be responsible for all development costs in China, Hong Kong, Taiwan and Macau. ...